The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The CRS-RS.5p predictive model of CRS after glofitamab treatment in patients with R/R DLBCL
Haifaa Abdulhaq, MD, University of California, San Francisco, CA, discusses the CRS-RS.5p predictive model to inform risk stratification and cytokine release syndrome (CRS) management following glofitamab treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
